NewcelX Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NCEL research report →
Price Chart
About the company
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
- CEO
- Ronen Twito
- IPO
- 2025
- Employees
- 11
- HQ
- Kloten, ZH, CH
Get TickerSpark's AI analysis on NCEL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.33M
- P/E
- 8.97
- PEG
- 0.04
- P/S
- 0.00
- P/B
- 2.87
- EV/EBITDA
- -0.27
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 21.75%
- ROIC
- -103.62%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-2,474,000
- Net Income
- $-8,300,000-319.0%
- EPS
- $-2.16+91.8%
- OCF Growth
- +35.2%
- FCF Growth
- +35.1%
- 52W High
- $19.10
- 52W Low
- $1.83
- 50D MA
- $3.27
- 200D MA
- $3.06
- Beta
- 0.93
- RSI (14)
- 43
- Avg Volume
- 13.42K
No earnings-call transcripts are available for NCEL yet.
- Free Float
- 100.0%
- Shares Outstanding
- 450.00K
- Float Shares
- 450.00K
of shares held by institutions
4 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Hrt Financial LP | 11.20K | ▲ 11.20K |
| Jones Financial Companies Lllp | 700 | ▲ 700 |
| Caitong International Asset Management Co., Ltd | 9 | ▲ 8 |
| Corecap Advisors, LLC | 3 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 27, 26 | Samuel Olivier | buy | 114,545 |
| Apr 27, 26 | Samuel Olivier | buy | 81,818 |
| Apr 27, 26 | Revel Michel | buy | 54,545 |
| Apr 27, 26 | Revel Michel | buy | 76,363 |
| Mar 18, 26 | Molakandov Kfir | other | 11,396 |
| Mar 18, 26 | Iohan Eran Israel | other | 9,117 |
| Mar 18, 26 | Galili Tamar | other | 9,117 |
| Mar 18, 26 | Twito Ronen | other | 0 |
| Mar 18, 26 | Revel Michel | other | 0 |
| Mar 18, 26 | Revel Michel | other | 9,117 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NCEL coverage
Recent articles, reports, and earnings notes.
No research on NCEL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NCEL report →NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes
globenewswire.com · Sep 28
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
globenewswire.com · Jul 31
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
globenewswire.com · Jul 8
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
globenewswire.com · Jul 1
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
globenewswire.com · Jun 15
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
globenewswire.com · May 27
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
globenewswire.com · Apr 30
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
globenewswire.com · Apr 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.